Cipla receives USFDA observations for its Goa manufacturing facility

Drug firm Cipla announced that it has received observations from United States Food and Drug Administration (USFDA) for its Goa manufacturing facility.

The US drug regulator classified the inspection conducted at Cipla's Goa manufacturing facility from September 16 to 27, 2019 as Official Action Indicated (OAI). The company, however, believes that this will not have any material impact on its US businesses.

Cipla further stated that it has a strong track record of maintaining the highest standard of compliance and would work closely with the agency to comprehensively address the observations received.

Cipla Limited is a pharmaceutical company offering products for therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health. The company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulisers and a range of inhaled accessory devices.

At 10.50 am on Thursday, the stock is trading at Rs 471.35, down by 0.08 per cent or Rs 0.40 per share. The 52-week high is recorded at Rs 585.50 and the 52-week low is Rs 389.55 on BSE.